Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
Zanubrutinib is indicated for the treatment of:
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy
A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia, Alessandria, Italy
A.O.U. Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy
Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning, China
Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou, China
Moffitt Cancer Center, Tampa, Florida, United States
Shanghai Cancer Center, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Ruijin Hospital, Shanghai, Shanghai, China
John Muir Medical Center, Concord, California, United States
University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
UCLA Department of Medicine Hematologyoncology, Los Angeles, California, United States
University of Miami, Miami, Florida, United States
Regenerative Medicine Center, Tianjin, Tianjin, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.